Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s
Antiviral Therapy · 2017-02 · 22 (2) · 113-126
DOI: 10.3851/imp3093 ↗At a glance
Randomisierte kontrollierte Studie in Antiviral Therapy, published online on 2016-02-01. Written by Theodoros Kelesidis and 9 co-authors. Institution: David Geffen School of Medicine at University of California - Los Angeles, Los Angeles, CA, USA. Major MEDLINE topics: Carotid Intima-Media Thickness. Cited 14 times so far (Crossref); 50 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.
Abstract (original language)
Background
The role of oxidized lipoproteins (high-density [HDLox] and low-density [LDLox]) and total lipoprotein particle (Lp) number and size in HIV-related cardiovascular disease (CVD) is unclear. The goal of this study was to evaluate changes of these biomarkers and their associations with rate of carotid intima media thickness progression over 3 years (ΔCIMT) in chronic HIV infection.
Methods
Prospective study of 234 HIV-infected anti-retroviral treatment-naive participants without CVD who were randomized to receive tenofovir-emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir or raltegravir (RAL) and achieved plasma HIV-1 RNA
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- David Geffen School of Medicine at University of California - Los Angeles, Los Angeles, CA, USA.
- Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
- Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- University Hospitals Case Medical Center, Cleveland, OH, USA.
Funding
- NIAID NIH HHS
- NCATS NIH HHS
- NHLBI NIH HHS
Cite
APA
Kelesidis, T., Tran, T. T. T., Brown, T. T., Moser, C., Ribaudo, H. J., Dube, M. P., Yang, O. O., McComsey, G. A., Stein, J. H., & Currier, J. S. (2017). Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. Antiviral Therapy, 22(2), 113-126. https://doi.org/10.3851/imp3093
Vancouver
Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, et al. Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. Antiviral Therapy. 2017;22(2):113-126. doi:10.3851/imp3093
BibTeX
@article{Kelesidis2017,
author = {Kelesidis, Theodoros and Tran, Thuy Tien T and Brown, Todd T and Moser, Carlee and Ribaudo, Heather J and Dube, Michael P and Yang, Otto O and McComsey, Grace A and Stein, James H and Currier, Judith S},
title = {Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s},
journal = {Antiviral Therapy},
year = {2017},
volume = {22},
number = {2},
pages = {113--126},
doi = {10.3851/imp3093}
}
EUVIMED